Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing

Reuters

06/14

<a href="https://laohu8.com/S/VVOS">Vivos Therapeutics</a> Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing

Vivos Therapeutics Inc. has announced the acquisition of Sleep Centers of Nevada $(SCN.AU)$, marking a strategic pivot towards expanding its sleep medicine and testing services. The transaction involved a $6 million cash payment and $1.5 million in Vivos common stock to SCN. An additional $1.5 million in Vivos common stock could be awarded if SCN achieves certain financial milestones. The acquisition is financed through a senior term loan from Streeterville Capital LLC and a private placement investment by New Seneca Partners. Vivos expects this acquisition to enhance its diagnostic and treatment revenues, aiming for cash flow positivity as SCN locations integrate Vivos treatments. CEO Kirk Huntsman expressed excitement about the acquisition, noting that SCN patient bookings are already fully scheduled.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015115), on June 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2543658580"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543658580\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2543658580?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-14 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543658580","market":"us","top_or_hot":-1,"title":"Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced the acquisition of Sleep Centers of Nevada <a href=\"https://laohu8.com/S/SCN.AU\">$(SCN.AU)$</a>, marking a strategic pivot towards expanding its sleep medicine and testing services. The transaction involved a $6 million cash payment and $1.5 million in Vivos common stock to SCN. An additional $1.5 million in Vivos common stock could be awarded if SCN achieves certain financial milestones. The acquisition is financed through a senior term loan from Streeterville Capital LLC and a private placement investment by New Seneca Partners. Vivos expects this acquisition to enhance its diagnostic and treatment revenues, aiming for cash flow positivity as SCN locations integrate Vivos treatments. CEO Kirk Huntsman expressed excitement about the acquisition, noting that SCN patient bookings are already fully scheduled.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015115), on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-14 05:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VVOS\">Vivos Therapeutics</a> Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vivos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has announced the acquisition of Sleep Centers of Nevada <a href=\"https://laohu8.com/S/SCN.AU\">$(SCN.AU)$</a>, marking a strategic pivot towards expanding its sleep medicine and testing services. The transaction involved a $6 million cash payment and $1.5 million in Vivos common stock to SCN. An additional $1.5 million in Vivos common stock could be awarded if SCN achieves certain financial milestones. The acquisition is financed through a senior term loan from Streeterville Capital LLC and a private placement investment by New Seneca Partners. Vivos expects this acquisition to enhance its diagnostic and treatment revenues, aiming for cash flow positivity as SCN locations integrate Vivos treatments. CEO Kirk Huntsman expressed excitement about the acquisition, noting that SCN patient bookings are already fully scheduled.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015115), on June 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健護理服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL7gXg3M:1","article_id":"2543658580","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543658580","pubTimestamp":1749848598,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vivos Therapeutics Inc. has announced the acquisition of Sleep Centers of Nevada , marking a strategic pivot towards expanding its sleep medicine and testing services. The transaction involved a $6 million cash payment and $1.5 million in Vivos common stock to SCN. An additional $1.5 million in Vivos common stock could be awarded if SCN achieves certain financial milestones. The acquisition is financed through a senior term loan from Streeterville Capital LLC and a private placement investment by New Seneca Partners. Vivos expects this acquisition to enhance its diagnostic and treatment revenues, aiming for cash flow positivity as SCN locations integrate Vivos treatments. CEO Kirk Huntsman expressed excitement about the acquisition, noting that SCN patient bookings are already fully scheduled.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","VVOS":"Vivos Therapeutics"},"translate_title":"Vivos Therapeutics完成对内华达州睡眠中心的收购，获得超过1100万美元的新融资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VVOS":0.9},"content_text":"Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing\n    \n\n        Vivos Therapeutics Inc. has announced the acquisition of Sleep Centers of Nevada $(SCN.AU)$, marking a strategic pivot towards expanding its sleep medicine and testing services. The transaction involved a $6 million cash payment and $1.5 million in Vivos common stock to SCN. An additional $1.5 million in Vivos common stock could be awarded if SCN achieves certain financial milestones. The acquisition is financed through a senior term loan from Streeterville Capital LLC and a private placement investment by New Seneca Partners. Vivos expects this acquisition to enhance its diagnostic and treatment revenues, aiming for cash flow positivity as SCN locations integrate Vivos treatments. CEO Kirk Huntsman expressed excitement about the acquisition, noting that SCN patient bookings are already fully scheduled.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-015115), on June 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}